Release Date: 08.31.2011
Presentation Type: Webinars
An interdisciplinary group of researchers from Boston have developed a microfluidic device that can test for the number of beneficial circulating endothelial progenitor cells (EPCs) in the blood stream of patients with cardiovascular disease. The number of EPCs in the blood can be used as a biomarker for risk assessment, disease progression and the response to therapy. Up to now, the measurement of EPCs in the bloodstream was very difficult and laborious and therefore, not very useful to physicians working with PH Patients at the bedside.
Dr. Hansmann and colleagues have attended the research room at PHA’s 2010 International Conference to apply the so called "EPC Capture Chip" in over 40 patients with PAH. They found the EPC numbers in PAH patients to be half the number in healthy controls. The new EPC capture chip has tremendous potential for serving as a rapid bedside tests to monitor treatment and disease progression.
The research team includes: Georg Hansmann; B.D. Plouffe; A. Hatch; A. Von Gise; H. Sallmon; Roham T. Zamanin; Shashi Murthy.